Edgar Filing: JOHNSON & JOHNSON - Form 8-K

JOHNSON & JOHNSON Form 8-K March 01, 2004

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8K

Current Report Pursuant to Section 13 or $15\,\mathrm{(d)}$ of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 1, 2004

JOHNSON & JOHNSON

(Exact name of registrant as specified in its charter)

New Jersey 1-3215 22-

1024240

(State or other Commission (I.R.S. Employer jurisdiction File Number) Identification

No.)

of incorporation)

One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933

(Address of principal executive offices) (zip code)

Registrant's telephone number including area code: (732) 524-0400 Item 5. Other Events.

On February 27, 2004, Johnson & Johnson ("J&J") issued the attached

press release announcing the strategic alliance with Guidant Corporation for the co-promotion of drug-eluting stents.

(c) Exhibit

Exhibit No. Description of Exhibit

Exhibit 99.17 Press Release dated February 27, 2004.

SIGNATURE

Edgar Filing: JOHNSON & JOHNSON - Form 8-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

JOHNSON & JOHNSON

Date: March 1, 2004 By: /s/ Stephen J. Cosgrove Stephen J. Cosgrove

Chief Accounting Officer